Kyverna Therapeutics targets autoimmune CAR T breakthrough after durable miv-cel results

Kyverna Therapeutics is moving closer to a potential commercial transformation after one-year miv-cel data strengthened the regulatory case for a single-dose CAR T-cell therapy in stiff person syndrome. The biotechnology company is already submitting portions of a rolling Biologics License Application and expects to complete the filing in the fourth quarter, potentially putting mivocabtagene autoleucel on a path toward becoming the first approved treatment specifically for stiff person syndrome and the first CAR T-cell therapy approved for an autoimmune disease. That possibility gives the latest durability update significance beyond another positive clinical readout: Kyverna Therapeutics is approaching the point where it must transition from developing an experimental cell therapy to building the manufacturing, treatment-center and reimbursement infrastructure required for a specialized launch. One-year results now show sustained mobility improvement while 92% of treated patients remained free of chronic immunotherapy, giving regulators additional evidence that the initial benefit did not disappear after the primary analysis.

The company also reported sustained responses extending to as long as 18 months in generalized myasthenia gravis, suggesting miv-cel could ultimately support a broader neuroimmunology franchise rather than a single rare-disease product. The commercial opportunity remains balanced by substantial uncertainty, however, because the stiff person syndrome filing relies on a 26-patient single-arm registrational trial, while the myasthenia gravis dataset includes only seven Phase 2 patients. Kyverna Therapeutics shares initially jumped in premarket trading but reversed sharply after the opening bell, showing that investors are looking beyond headline durability toward the FDA review, commercial execution and whether the clinical profile holds up in larger controlled studies.

One-year mobility gains strengthen the argument that a single miv-cel treatment could replace chronic therapy

The KYSA-8 registrational trial enrolled 26 adults with stiff person syndrome who had experienced an inadequate response to at least one immunotherapy. Patients received lymphodepletion followed by one infusion of miv-cel, a fully human autologous CD19-targeted CAR T-cell therapy engineered with CD28 co-stimulation.

The primary analysis had already shown a median 46% improvement from baseline in the Timed 25-Foot Walk at Week 16. That improvement reached 49% at Month 12, while 95% of patients who previously achieved a clinically meaningful response maintained that benefit through one year. More than one-third of participants completed the walking assessment in under five seconds, and among 12 patients who required a walking aid before treatment, 67% continued to walk without assistance at the one-year assessment.

Those findings matter because stiff person syndrome can progressively erode mobility through severe muscle stiffness and painful spasms. Kyverna Therapeutics estimates that approximately 6,000 patients are diagnosed with the disorder in the United States, and there are currently no FDA-approved therapies specifically for the disease. Current treatment can include intravenous immunoglobulin, rituximab, plasmapheresis and symptomatic therapy, frequently requiring repeated or chronic intervention.

Miv-cel is designed around a fundamentally different treatment model. Rather than repeatedly suppressing the immune system, the CAR T-cell therapy aims to deeply deplete CD19-positive B cells involved in producing disease-driving autoantibodies and potentially reset the immune system after a single treatment.

The continued reduction in chronic immunotherapy use therefore becomes commercially and clinically important. At one year, 92% of KYSA-8 patients remained free of chronic immunotherapies for stiff person syndrome. If that treatment independence proves durable, miv-cel could compete not simply on symptom improvement but on reducing years of ongoing therapy and associated healthcare utilization.

Kyverna Therapeutics has been careful to frame this as the potential for durable remission rather than evidence of a permanent cure. B-cell populations can eventually recover following CAR T therapy, and longer follow-up will be required to determine whether autoimmune symptoms return and whether some patients eventually require additional treatment.

Favorable safety could become a major competitive advantage as autoimmune CAR T development expands

The safety profile remains one of the more commercially important aspects of the miv-cel program. Through one year in KYSA-8, Kyverna Therapeutics reported no high-grade cytokine release syndrome, no immune effector cell-associated neurotoxicity syndrome and no cases of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. The company has now treated more than 100 patients with miv-cel across autoimmune indications without observing those high-grade complications.

That does not remove the risks associated with CAR T-cell therapy. Patients still undergo lymphodepletion before treatment, and CAR T administration requires specialized monitoring and medical infrastructure. The safety database also remains much smaller than those supporting established therapies used across broader autoimmune populations.

Still, an ability to deliver deep immune resetting without severe CAR T-associated toxicity could materially influence how broadly the technology can move outside oncology. Autoimmune diseases may involve substantially larger populations than many blood cancers, making tolerability, outpatient feasibility and treatment-center capacity particularly important for commercial scalability.

Kyverna Therapeutics has already said it is exploring alternative or potentially no preconditioning approaches and the possibility of outpatient administration. If future studies support those strategies, the economics and accessibility of miv-cel could change substantially because treatment would become less dependent on the intensive infrastructure traditionally associated with oncology CAR T therapy.

The company has also received FDA Regenerative Medicine Advanced Therapy designations for miv-cel in stiff person syndrome, generalized myasthenia gravis and non-active secondary progressive multiple sclerosis. Those designations do not predict approval, but they provide additional opportunities for interaction with regulators as Kyverna Therapeutics attempts to establish a broader neuroimmunology franchise.

Generalized myasthenia gravis could greatly expand the commercial opportunity beyond stiff person syndrome

Stiff person syndrome offers Kyverna Therapeutics a potential first launch market, but generalized myasthenia gravis represents a much larger opportunity.

The company estimates approximately 80,000 patients are diagnosed with generalized myasthenia gravis in the United States. The disease is driven by pathogenic antibodies that disrupt communication between nerves and muscles, producing weakness that can affect movement, swallowing, speech and breathing. Patients may require chronic corticosteroids, immunosuppressants, complement inhibitors or FcRn-targeted therapies.

Kyverna Therapeutics reported that all seven participants in the Phase 2 portion of KYSA-6 achieved clinically meaningful improvement on both Myasthenia Gravis Activities of Daily Living and Quantitative Myasthenia Gravis measures at 24 weeks. Among the five patients who have now reached at least one year of follow-up, clinically meaningful benefits were maintained across major disease measures.

Minimal symptom expression was maintained in 57% of patients at the latest assessment, while six of seven remained off immunosuppressive therapy. All seven had been free of myasthenia gravis immunotherapies at Week 24.

The dataset is too small to establish a commercial treatment profile, but a randomized Phase 3 portion of KYSA-6 is now underway. The approximately 60-patient global study compares miv-cel with standard of care and uses MG-ADL and QMG as co-primary endpoints. Enrollment is expected to be completed by mid-2027.

A successful controlled trial would significantly broaden the miv-cel opportunity and provide stronger evidence that the immune-reset approach works across B-cell-driven neurological autoimmune diseases. It would also give Kyverna Therapeutics a much larger potential patient base following any initial stiff person syndrome launch.

Kyverna Therapeutics has begun building launch infrastructure while its balance sheet supports the FDA process

Kyverna Therapeutics is already preparing for commercialization rather than waiting for a final FDA decision. The company has recruited a chief commercial officer and said its activities include activating potential treatment centers, planning supply, working with payers and patient-advocacy organizations and preparing broader launch capabilities.

Those investments are becoming increasingly relevant because CAR T commercialization requires considerably more coordination than launching a conventional pill or injectable biologic. Patients need cells collected, genetically modified, manufactured and returned for infusion, meaning scheduling, manufacturing reliability and treatment-center logistics are integral parts of the product itself.

The company ended June with $199.4 million in cash, cash equivalents and marketable securities. Together with borrowing capacity under its amended Oxford Finance facility, management expects those resources to fund operations into 2028. Research and development expenses were $24.8 million during the second quarter, while general and administrative expenses reached $14.8 million and quarterly net loss totaled $38.3 million.

That runway should cover the current stiff person syndrome regulatory process and continued Phase 3 development in generalized myasthenia gravis, although a successful commercial launch would require additional investment in manufacturing and treatment-center infrastructure.

The rolling BLA is particularly important because the Chemistry, Manufacturing and Controls portion is already being submitted, while Kyverna Therapeutics expects to complete the full application during the fourth quarter. The company intends to include the new one-year KYSA-8 results, and full data will be presented at the joint ACTRIMS-ECTRIMS meeting in October.

FDA acceptance and any Priority Review decision would then determine the next regulatory timeline. Approval is not assured, especially because KYSA-8 is a single-arm Phase 2 registrational study rather than a randomized pivotal trial. Regulators will need to determine whether the magnitude and durability of the effect, combined with stiff person syndrome’s rarity and lack of approved treatments, provide sufficient evidence of benefit.

Kyverna Therapeutics stock reverses early rally as investors focus on regulatory and execution risk

The stock reaction illustrates the tension between encouraging clinical durability and the uncertainty still surrounding commercialization. Kyverna Therapeutics shares traded as high as $7.92 after opening at $7.80, following the previous close near $7.07, but reversed sharply and were trading around $6.80 later in the morning, down roughly 4%. Trading volume quickly rose above recent averages.

There was no obvious adverse clinical development in the release that explains the reversal. The move instead suggests investors may have entered the announcement expecting strong one-year durability after the earlier Week 16 results, leaving the stock vulnerable once the anticipated positive data were confirmed.

The company’s market capitalization was approximately $420 million during trading, while six analysts tracked by StockAnalysis carried a Strong Buy consensus and an average target of $30.40. Those estimates imply considerable upside but should be viewed cautiously because Kyverna Therapeutics remains a pre-commercial biotechnology company whose valuation depends heavily on FDA decisions and relatively small clinical datasets.

The next catalysts could therefore matter more than the one-year headline itself. Completion and acceptance of the BLA, presentation of the full KYSA-8 dataset, FDA review timing and continued Phase 3 enrollment in generalized myasthenia gravis will determine whether miv-cel moves from a promising autoimmune CAR T program toward a viable commercial franchise.

For Kyverna Therapeutics, the latest results strengthen an increasingly unusual proposition: one treatment could potentially provide prolonged disease control while reducing dependence on chronic immunotherapy. The one-year data support that possibility. The FDA review will determine whether the evidence is mature enough to bring that model into clinical practice.

Key takeaways from Kyverna Therapeutics’ miv-cel durability data and FDA strategy

• Miv-cel maintained a 49% median improvement in the Timed 25-Foot Walk at one year in the 26-patient KYSA-8 stiff person syndrome trial.
• About 95% of patients who previously achieved a clinically meaningful mobility improvement maintained that benefit.
• Approximately 92% of patients remained free of chronic stiff person syndrome immunotherapies at one year.
• Kyverna Therapeutics plans to include the new durability data in its rolling Biologics License Application and complete the submission in the fourth quarter.
• Miv-cel could become the first FDA-approved treatment specifically for stiff person syndrome and potentially the first CAR T-cell therapy approved for autoimmune disease.
• Longer-term generalized myasthenia gravis data also showed sustained benefits, with six of seven Phase 2 patients remaining off immunosuppressants at latest follow-up.
• The randomized Phase 3 KYSA-6 study in generalized myasthenia gravis is expected to finish enrollment by mid-2027.
• Kyverna Therapeutics held $199.4 million in cash and investments at June 30 and expects its operating runway to extend into 2028.
• Shares reversed an early rally despite the positive results as investors weighed FDA risk, small clinical datasets and commercial execution.
• FDA acceptance of the rolling filing and the subsequent regulatory review now represent the most important near-term catalysts for Kyverna Therapeutics.